Top 10 Global CDMO Rankings in 2022

In recent years, the global CDMO industry has maintained steady growth. In terms of revenue, Lonza of Switzerland ranks first, with sales of 5.4 billion Swiss francs in 2021, a year-on-year increase of 20%. Followed by the two companies of WuXi, WuXi AppTec and WuXi Biologics, the total revenue was US$5.214 billion, a year-on-year increase of 49.83%, and the total number of employees was nearly 45,000.

From the top 10, there are 9 companies with revenue of more than 1 billion US dollars. Two companies from China and South Korea are on the list. The rest are European and American companies, and there is only one Catalent in the United States. From the perspective of revenue growth, WuXi has grown by 50% year-on-year last year, far exceeding other companies.

Catalent's revenue last year was $3.998 billion, a year-on-year increase of 29%, ranking third. In March 2013, Catalent established the 8th clinical supply center in the world and the 1st clinical supply center in China, and named its Chinese company after "Catalent".

Swiss CDMO company Recipharm ranked fifth. On April 11, 2022, it announced the completion of the acquisition of advanced therapy CDMO Arranta Bio and gene therapy CDMO Vibalogics, expanding the field of biopharmaceutical CDMOs. On January 10, 2021, Pharmaron announced the successful acquisition of Aesica Pharmaceuticals, a subsidiary of Recipharm in Cramlington, UK, to enhance the overall strength of the small molecule CDMO service platform.

WuXi Biologics had revenue of $1.6 billion last year, and its arch-rival South Korea’s Samsung Biologics had revenue of $1.226 billion last year, a year-on-year increase of 34.6%. In the field of biopharmaceutical CDMOs, WuXi Biologics has the second largest market share in the world, with more than 9,800 employees.

Boehringer Ingelheim's net sales in 2021 will reach 20.6 billion euros, a year-on-year increase of 7.5%. Among them, the biopharmaceutical CDMO business achieved net sales of 917 million euros, a year-on-year increase of 9.5%. Boehringer Ingelheim covers the entire biopharmaceutical value chain, from the development and production process of producer cells (mammalian cells and microorganisms), to the production of active substances and finished pharmaceutical products, to product launch and global market supply. The company's total investment in the research pipeline is expected to exceed EUR 25 billion over the next five years.

According to WuXi Biologics' public materials, FUJIFILM Diosynth Biotechnologies' biopharmaceutical CDMO business ranks 5th, but no data has been published.

Judging from the Top 10 rankings, WuXi is likely to rank first in the future. Other Chinese companies such as Asymchem, whose CDMO business revenue has reached US$730 million, will also enter the top 10 in the future.